Log in or Sign up for Free to view tailored content for your specialty!
Inflammatory Bowel Disease News

Tremfya’s FDA win as fully subcutaneous option for Crohn’s may pave way to eclipse Stelara
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous induction options for the treatment of moderately to severely active Crohn’s disease, Johnson & Johnson reported.
Etrasimod can be safely used alongside opioids, antidepressants in ulcerative colitis

Using etrasimod with opioids or antidepressants did not increase risk for serotonin syndrome-associated adverse events among patients with ulcerative colitis, according to a study published in United European Gastroenterology Journal.
Q&A: Wearable devices may help IBD patients track flares in ‘the comfort of their homes’

Physiological metrics captured via wearable devices may help identify and predict flares in inflammatory bowel disease, Robert P. Hirten, MD, told Healio, and could potentially play a role in remote monitoring of disease activity.
Log in or Sign up for Free to view tailored content for your specialty!
First four Stelara biosimilars launch in US; ‘white labeling’ threatens market ‘vibrancy’

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference product manufacturer, Janssen Pharmaceuticals, which set timelines for their market entries.
Q&A: ‘Everyone benefits’ from noninvasive, individualized monitoring in pediatric IBD

SAN FRANCISCO — Noninvasive monitoring methods, such as enterography and ultrasound, are becoming increasingly recognized as essential tools in the management of pediatric patients with inflammatory bowel disease, according to presenters.
Oral vancomycin may offer ‘viable option’ for IBD-related primary sclerosing cholangitis

Oral vancomycin therapy resulted in clinical response in nearly half of patients with inflammatory bowel disease associated with primary sclerosing cholangitis, according to a study published in Therapeutic Advances in Gastroenterology.
VIVID-2: Omvoh demonstrates ‘continued durability,’ safety in Crohn’s disease at 2 years

SAN FRANCISCO — Most patients with moderately to severely active Crohn’s disease who achieved endoscopic response and remission after 52 weeks of Omvoh therapy maintained those results through 104 weeks, according to VIVID-2 study results.
Stelara, Entyvio have ‘comparable’ cardiovascular safety profiles in older adults with IBD

SAN FRANCISCO — Although Stelara and Entyvio demonstrated similar cardiovascular safety profiles among older patients with inflammatory bowel disease, Stelara was associated with reduced all-cause mortality risk over 3 years, data showed.
Train support staff to be aware of mental health concerns in IBD to avoid future trauma

SAN FRANCISCO — Patients with inflammatory bowel disease remain at higher risk for mental health disorders, but training support staff to recognize the symptoms could be key to preventing further traumatization, noted a presenter here.
Most patients with IBD ‘still experience significant challenges’ accessing, affording care

SAN FRANCISCO — Despite advances in treatment for inflammatory bowel disease, more than 55% of patients report medication delays, mostly due to insurance challenges, and many make financial trade-offs to afford care, survey results showed.
-
Headline News
Cancer surgeon runs the globe to raise testicular cancer awareness
March 21, 20258 min read -
Headline News
FDA launches online database for chemical containment levels in food
March 20, 20251 min read -
Headline News
‘Early events’ can increase a person’s risk for long COVID
March 20, 20253 min read
-
Headline News
Cancer surgeon runs the globe to raise testicular cancer awareness
March 21, 20258 min read -
Headline News
FDA launches online database for chemical containment levels in food
March 20, 20251 min read -
Headline News
‘Early events’ can increase a person’s risk for long COVID
March 20, 20253 min read